The other possible mechanism of the benefits of RAAS inhibition in the athogenesis of COVID-19

Clin Cardiol. 2020 Dec;43(12):1349. doi: 10.1002/clc.23494. Epub 2020 Nov 11.

Authors

Neelesh Gupta¹, Krunalkumar Patel², Rajeev Gupta³

Affiliations

¹ Department of Internal Medicine, Nazareth Hospital, Philadelphia, Pennsylvania, USA.
² Department of Internal Medicine, St Mary Medical Center, Langhorne, Pennsylvania, USA.
³ Mediclinic, Al-Jowhara Hospital, Al Ain, UAE.

No abstract available

Publication types

Letter
Comment

MeSH terms

Angiotensin Receptor Antagonists*
Angiotensin-Converting Enzyme Inhibitors
COVID-19*
Humans
Inflammation
Pandemics
Renin-Angiotensin System
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors